Teva Pharmaceutical Industries and Samsung Bioepis have entered a license and commercialization agreement for OPUVIZ (aflibercept), a biosimilar referencing Eylea, in the Canadian market.
Under the agreement, Samsung Bioepis will handle product registration and manufacturing, while Teva Canada will be responsible for commercialization activities. The arrangement is intended to support broader access to aflibercept-based therapy in ophthalmology, adding to Teva’s biosimilars portfolio in Canada and Samsung Bioepis’ presence in North America.
OPUVIZ received Health Canada approval in October 2025. It is indicated for neovascular (wet) age-related macular degeneration, visual impairment due to macular edema secondary to central or branch retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization.
Aflibercept is an anti-VEGF biologic widely used to treat retinal diseases associated with abnormal blood vessel growth and leakage. Biosimilar versions are expected to play a role in expanding treatment options and potentially easing cost pressures in ophthalmic care.
Samsung Bioepis’ aflibercept biosimilar is already available in Europe and the Republic of Korea, and the new agreement extends its reach into Canada through Teva’s local infrastructure.
The deal reflects continued momentum in the ophthalmology biosimilars segment, where companies are pursuing partnerships to combine manufacturing expertise with established commercial networks.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!